Wall Street brokerages predict that DiaMedica Therapeutics Inc (NASDAQ:DMAC) will post earnings per share of ($0.28) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for DiaMedica Therapeutics’ earnings. DiaMedica Therapeutics reported earnings of ($0.40) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 30%. The firm is scheduled to report its next quarterly earnings results on Wednesday, September 4th.
On average, analysts expect that DiaMedica Therapeutics will report full year earnings of ($1.10) per share for the current fiscal year. For the next financial year, analysts forecast that the company will report earnings of ($1.62) per share. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow DiaMedica Therapeutics.
DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Monday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05).
Several brokerages recently commented on DMAC. Lake Street Capital started coverage on DiaMedica Therapeutics in a report on Tuesday, March 5th. They set a “buy” rating and a $9.00 target price on the stock. Dougherty & Co began coverage on shares of DiaMedica Therapeutics in a report on Tuesday, April 30th. They set a “buy” rating and a $8.00 price target on the stock.
NASDAQ:DMAC remained flat at $$2.70 during mid-day trading on Monday. The company had a trading volume of 4,425 shares, compared to its average volume of 40,785. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.49 and a quick ratio of 13.87. DiaMedica Therapeutics has a fifty-two week low of $2.46 and a fifty-two week high of $4.80.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in DiaMedica Therapeutics in the first quarter valued at approximately $47,000. Worth Venture Partners LLC bought a new position in DiaMedica Therapeutics in the fourth quarter valued at $377,000. Finally, Wexford Capital LP acquired a new stake in DiaMedica Therapeutics in the fourth quarter valued at $1,382,000. Institutional investors own 8.67% of the company’s stock.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Further Reading: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.